Brief: Fate Therapeutics Selected For U.S. FDA Chemistry, Manufacturing, And Controls Development And Readiness Pilot Program To Support Manufacturing Readiness Of Ft819
05/05/2026 13:37
May 5 (Reuters) - Fate Therapeutics Inc FATE.O: FATE THERAPEUTICS SELECTED FOR U.S. FDA CHEMISTRY, MANUFACTURING, AND CONTROLS DEVELOPMENT AND READINESS PILOT PROGRAM TO SUPPORT MANUFACTURING READINESS OF FT819 Source text: ID:nGNX5zJJT Further company coverage: FATE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fate Therapeutics
See all newsBrief: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial Of FT819 For The Treatment Of Lupus Nephritis
Fate Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Fate Therapeutics Q2 loss narrows as expenses fall, revenue rises
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview